Select Language:
A major pharmaceutical company based in the UK and Sweden plans to invest $15 billion in China over the next five years to expand its manufacturing, research, and development efforts within the country. This comprehensive investment will span the entire value chain, from early drug discovery and clinical trials to production, allowing the company to bring its innovative products developed in China to global markets.
The initiative aims to enhance capabilities in cell therapy and radiopharmaceutical conjugate drugs, supporting the growth of a diverse pipeline of medicines. These advancements are expected to benefit patients battling cancer, blood disorders, and autoimmune conditions. Notably, the company will become the first international pharmaceutical firm in China to develop full end-to-end cell therapy capabilities.
This move signifies a new chapter in the company’s growth in China. The CEO highlighted that China has become a key player in scientific innovation, advanced manufacturing, and global health. By expanding its expertise in breakthrough treatments such as cell therapy and radiopharmaceuticals, the company intends to make significant contributions to China’s high-quality development and deliver next-generation therapies to more patients.
Since the beginning of 2023, the company has invested over $1.8 billion into its manufacturing operations in China. Its research and development pipeline in the country includes more than 200 projects, with 10 to 15 new initiatives launched annually.
ChatGPT
Perplexity
Gemini AI
Grok AI
